OverviewChartNewsTraderScreen

Soc. Generale Knock-Out Genmab AS/  DE000SW88438  /

Frankfurt Zert./SG
5/17/2024  9:35:16 PM Chg.-0.330 Bid9:56:12 PM Ask9:56:12 PM Underlying Strike price Expiration date Option type
12.970EUR -2.48% 12.980
Bid Size: 500		 13.220
Ask Size: 500		 - 3,014.0243 DKK 12/31/2078 Put
GlobeNewswire 5/17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire 5/14 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...
GlobeNewswire 5/14 Immatics Announces First Quarter 2024 Financial Results and Business Update
GlobeNewswire 5/6 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 5/2 Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 4/30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 4/22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 4/7 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire 4/3 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire 3/20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 3/20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire 3/11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire 3/7 BioNTech Announces Planned Retirement of Sean Marett
GlobeNewswire 3/6 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire 3/4 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...
GlobeNewswire 2/14 Genmab Announces Initiation of Share Buy-Back Program
GlobeNewswire 2/14 Genmab Publishes 2023 Annual Report
GlobeNewswire 2/8 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 2/8 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 1/31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire 1/22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
GlobeNewswire 1/9 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 12/21/2023 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire 12/18/2023 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire 12/12/2023 BioNTech to Inaugurate First African Site on December 18, 2023